Synthesis and Evaluation of N‐Phenylpyrrolamides as DNA Gyrase B Inhibitors
Citations Over TimeTop 14% of 2017 papers
Abstract
ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes of antibacterial drugs that are unrepresented in the antibacterial pipeline. We developed 32 new N-phenylpyrrolamides and evaluated them against DNA gyrase and topoisomerase IV from E. coli and Staphylococcus aureus. Antibacterial activities were studied against Gram-positive and Gram-negative bacterial strains. The most potent compound displayed an IC50 of 47 nm against E. coli DNA gyrase, and a minimum inhibitory concentration (MIC) of 12.5 μm against the Gram-positive Enterococcus faecalis. Some compounds displayed good antibacterial activities against an efflux-pump-deficient E. coli strain (MIC=6.25 μm) and against wild-type E. coli in the presence of efflux pump inhibitor PAβN (MIC=3.13 μm). Here we describe new findings regarding the structure-activity relationships of N-phenylpyrrolamide DNA gyrase B inhibitors and investigate the factors that are important for the antibacterial activity of this class of compounds.
Related Papers
- → Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition(1994)162 cited
- → Biological and docking studies of topoisomerase IV inhibition by thiosemicarbazides(2010)34 cited
- → Roles of DNA Topoisomerases in Chromosomal Replication and Segregation(1994)44 cited
- → Design and synthesis of peptides from bacterial ParE toxin as inhibitors of topoisomerases(2012)15 cited
- → DNA Topoisomerases from Streptomyces and Their Inhibition by Some Antibiotic and Antitumoractive Agents(1991)1 cited